Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J.

Cancer Immunol Immunother. 2011 Dec;60(12):1789-800. doi: 10.1007/s00262-011-1072-9. Epub 2011 Jul 27.

PMID:
21792658
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.

Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD, Sondel P.

J Immunother. 2004 May-Jun;27(3):211-9.

PMID:
15076138
[PubMed - indexed for MEDLINE]
3.

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. doi: 10.1007/s00262-013-1430-x. Epub 2013 May 10.

PMID:
23661160
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM.

Clin Cancer Res. 1996 Dec;2(12):1951-9.

PMID:
9816154
[PubMed - indexed for MEDLINE]
Free Article
5.

The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.

Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Res. 2001 Feb 15;61(4):1500-7.

PMID:
11245457
[PubMed - indexed for MEDLINE]
Free Article
6.

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.

Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM.

J Leukoc Biol. 2011 Apr;89(4):625-38. doi: 10.1189/jlb.0710422. Epub 2011 Jan 19.

PMID:
21248148
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.

Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.

Clin Cancer Res. 2004 Jul 15;10(14):4839-47.

PMID:
15269160
[PubMed - indexed for MEDLINE]
Free Article
8.

Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.

PMID:
18438664
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells.

Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM.

Immunol Lett. 1993 Dec;39(1):91-9.

PMID:
8144194
[PubMed - indexed for MEDLINE]
10.

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.

Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP, Patankar MS.

Mol Cancer. 2010 Jan 20;9:11. doi: 10.1186/1476-4598-9-11.

PMID:
20089172
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Targeting activity of a TCR/IL-2 fusion protein against established tumors.

Wen J, Zhu X, Liu B, You L, Kong L, Lee HI, Han KP, Wong JL, Rhode PR, Wong HC.

Cancer Immunol Immunother. 2008 Dec;57(12):1781-94. doi: 10.1007/s00262-008-0504-7. Epub 2008 Mar 28.

PMID:
18369620
[PubMed - indexed for MEDLINE]
12.

Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.

Gottschalk N, Lang S, Kimmig R, Singh M, Brandau S.

BMC Cancer. 2012 Oct 4;12:451. doi: 10.1186/1471-2407-12-451.

PMID:
23036052
[PubMed - indexed for MEDLINE]
Free PMC Article
13.
14.

Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd.

Surgery. 2012 Sep;152(3):431-40. doi: 10.1016/j.surg.2012.05.035. Epub 2012 Jul 6.

PMID:
22770960
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM.

Clin Cancer Res. 2009 Sep 15;15(18):5923-30. doi: 10.1158/1078-0432.CCR-08-2963. Epub 2009 Sep 8.

PMID:
19737959
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27.

PMID:
22844125
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells.

Rabinowich H, Herberman RB, Whiteside TL.

Cell Immunol. 1993 Dec;152(2):481-98.

PMID:
7903063
[PubMed - indexed for MEDLINE]
19.

Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.

Hallett WH, Ames E, Alvarez M, Barao I, Taylor PA, Blazar BR, Murphy WJ.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1088-99. doi: 10.1016/j.bbmt.2008.08.001.

PMID:
18804038
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.

Liu Z, Lee FT, Hanai N, Smyth FE, Burgess AW, Old LJ, Scott AM.

Cancer Immun. 2002 Oct 7;2:13.

PMID:
12747758
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk